左甲状腺素治疗充分性与制剂更换:美国真实世界数据的回顾性研究
该回顾性研究分析2013年3月至2020年2月美国Optum临床与理赔数据库中接受左甲状腺素(LT4)治疗的甲状腺功能减退患者,81.1%的患者TSH达到正常范围,24.9%的患者在12个月内至少更换一次LT4制剂,41.4%在24个月内至少更换一次,Medicare保险患者较商业保险患者更常更换制剂(26.2% vs 23.1%,p<0.001)。
要点
- 81.1%接受LT4治疗的患者TSH达到正常范围(0.45-4.5 mIU/L)。
- 24.9%的患者在12个月内至少更换一次LT4制剂,41.4%在24个月内至少更换一次。
- Medicare保险患者较商业保险患者更常更换LT4制剂(26.2% vs 23.1%,p<0.001)。
核心结论
- 多数接受LT4治疗的患者维持正常TSH水平,较既往报告有所改善;建议持续医生参与和患者教育以进一步减少TSH未达标患者。
- 约25%的患者在1年内更换LT4制剂,>40%在2年内更换,与临床推荐相悖;更换者中多数仅更换一次。
研究设计与样本
- 回顾性研究,数据来源于美国Optum临床与理赔数据库,分析2013年3月至2020年2月接受LT4治疗的甲状腺功能减退成人患者。
- 目标1纳入以随机选取的TSH结果索引、且至少有2次间隔1-15个月的TSH结果的患者(n/N=9130/11,259)。
- 目标2纳入以随机选取的LT4药房理赔索引、且至少有2次间隔≥1个月的LT4理赔及随访期间至少1次理赔的患者(N=25,076)。
- 所有数据采用描述性统计,按年龄组、性别和保险类型分层。
主要发现
- 索引TSH组中81.1%的患者达到正常TSH值(置信区间:80.4-81.8;n/N=9130/11,259)。
- 按年龄组、性别和保险类型分层后,各亚组中≥70%的患者随访时平均TSH值正常。
- 目标2中24.9%(N=6238)的LT4索引组患者在12个月内至少更换一次制剂,其中67.3%仅更换一次。
- 41.4%(N=10,370)的患者在长达24个月内至少更换一次制剂。
- Medicare保险患者较商业保险患者更换制剂的比例显著更高(26.2% vs 23.1%,p<0.001)。
关键数值与推荐
- TSH正常范围定义为0.45-4.5 mIU/L,低值为<0.45 mIU/L,高值为>4.5 mIU/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The prevalence of hypothyroidism (HT) has increased over time. To assess the effectiveness of treatment, we (1) studied thyrotropin (TSH) levels among patients receiving levothyroxine (LT4) and (2) determined the percentages of patients switching among LT4 formulations. Methods: Data on patients with HT receiving LT4 from the Optum™ Clinical and Claims Database were analyzed from March 2013 through February 2020. Eligible adult patients had ≥1 medical claim with an HT diagnosis and all patients were observed for ≥12 months. Patients included in Objective 1 were indexed on a randomly selected TSH result and had ≥2 results for TSH 1-15 months apart. Patients included in Objective 2 were indexed on a randomly selected LT4 pharmacy claim and had ≥2 LT4 claims ≥1 month apart and ≥1 claim during follow-up. Outcomes were the proportion of patients with low, normal, or high (<0.45, 0.45-4.5, or >4.5 mIU/L, respectively) TSH levels and the proportion of patients switching LT4 formulations, respectively. Data were stratified by age group, sex, and insurance type. All data reported were analyzed using descriptive statistics. Results: Of patients who were in the indexed TSH group, 81.1% [confidence intervals: 80.4-81.8; n/N = 9130/11,259] achieved normal TSH values. When stratified by age group, sex, and insurance type, ≥70% of patients in each of these subgroups exhibited normal mean TSH values at follow-up. For Objective 2 (N = 25,076), 24.9% (N = 6238) of the LT4-indexed group had ≥1 formulation switch in 12 months, of which 67.3% only switched once, and 41.4% (N = 10,370) had ≥1 formulation switch in up to 24 months. A significantly higher proportion of Medicare vs. commercially insured patients had switched formulations (26.2% vs. 23.1%, p < 0.001). Conclusions: Most LT4-treated patients maintain normal TSH levels, which is an improvement vs. previous reports. Continued physician engagement and patient education are advised to further reduce the number of patients who maintain off-target TSH levels. Contrary to clinical recommendations, about 25% of patients receiving LT4 switched formulations within 1 year, with >40% switching within 2 years; among patients who switched, most only switched once.
引用
- Bianco AC, Bao Y, Antunez Flores O, et al. Levothyroxine Treatment Adequacy and Formulation Changes in Patients with Hypothyroidism: A Retrospective Study of Real-World Data from the United States. Thyroid. 2023. PMID: 37335236. doi:10.1089/thy.2022.0382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。